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A B S T R A C T
Aims: To evaluate the pharmacokinetics and pharmacodynamics of basal insulin glargine with meal-
time insulin glulisine or twice daily 75/25 premixed neutral protamine insulin lispro and insulin lispro
in individuals with type 1 diabetes during three standardized meals over a 24 hour duration and compare
to physiologic insulin and glucose responses in healthy non-diabetic individuals.
Methods: Twelve healthy (4male/8 female) and thirteen individuals with type 1 diabetes (8 male/5 female)
were studied during three sequential standardized meals. Individuals with type 1 diabetes received either
glargine and glulisine injected 5 minutes subcutaneously before each meal or premixed insulin lispro
injected 5 minutes before breakfast and dinner in a randomized fashion separated by eight weeks.
Results: The incremental systemic insulin AUC, maximal insulin concentration, and rate of rise of sys-
temic insulin (0–30 minutes) during all three meal intervals were similar between glargine/glulisine and
healthy controls. Incremental glucose AUC with glargine/glulisine was similar to controls at lunch and
dinner. With premix 75/25 insulin, insulin AUC was lower and incremental glucose AUC was greater at
lunch compared to the healthy and glargine/glulisine. Hypoglycemic events before lunch were greater
with premix insulin group than with glargine/glulisine (p < 0.0001).
Conclusions: Glargine/glulisine pharmacokinetics in type 1 diabetes can closely approximate physiolog-
ic insulin responses in healthy individuals during a day in which three standardized meals are consumed.
Additionally, when glulisine is dosed only ﬁve minutes pre-meal, systemic insulin concentration rises
as rapidly as prandial endogenous insulin levels. This present study compared glargine and glulisine ad-
ministered in an approximate 50/50 proportion. Future studies of alternate meal times, meal content
and differing premixed insulin preparations are indicated.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
In healthy individuals, low levels of circulating insulin are main-
tained during interprandial periods, while during a meal, insulin
levels rise rapidly and then taper to fasting concentrations as glucose
levels return to baseline [1]. In order to improve glycemic control
and reduce microvascular complications in patients with diabe-
tes, substantial effort has been directed toward the development
of insulin analog formulations, delivery methods and dosing sched-
ules that more closely match physiologic insulin proﬁles [2].
One common insulin replacement regimen involves multiple
daily injections (basal-bolus therapy), consisting of a longer-
acting insulin (insulin glargine, degludec, detemir, or NPH insulin
injected once or twice daily) and rapid-acting insulin (glulisine,
aspart or lispro) injected prior to a meal to provide prandial
insulin coverage. Another option for insulin replacement is pre-
mixed analog insulin, typically injected twice daily, which contains
either neutral protamine lispro and insulin lispro (as a 75:25
ratio) or protamine crystalline aspart and insulin aspart (as a
70:30 ratio). The protamine portion of premix insulin is similar to
NPH insulin and functions as intermediate-acting insulin
to cover basal insulin requirements. The rapid-acting component
is aimed to cover breakfast and dinner prandial insulin
requirements [3].
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While pharmacokinetic (PK) and pharamacodynamic (PD) studies
of long-acting and rapid-acting insulin analogs have been
published [4,5], previous studies often involved injection of these
insulins under fasting conditions or involved injection prior to only
one standardized meal challenge. Comparison groups usually con-
sisted of patients receiving regular human insulin and/or NPH insulin
as part of their basal-bolus therapy. To further examine the PK and
PD of insulin analogs used in contemporary basal-bolus regimens
in the treatment of type 1 diabetes mellitus, the aim of this study
was to determine an entire day-long proﬁle of insulin and glucose
levels over the course of three standardized meal challenges. Insulin
glargine (glargine) was injected prior to breakfast, and insulin
glulisine (glulisine) was used as the pre-meal bolus insulin. A com-
parison group of non-diabetic healthy individuals served as a control
group to demonstrate normal physiologic insulin and glucose re-
sponses during the three meals. A second comparison group
consisted of patients with type 1 diabetes who consumed all three
standardized meals and received pre-mixed injections of neutral
protamine lispro and insulin lispro prior to breakfast and dinner.
Subjects
All healthy subjects had normal liver, kidney, electrolyte and blood
count values and had a normal response to an oral glucose toler-
ance test. Individuals with type 1 diabetes also had normal liver,
kidney, electrolyte and blood count values. Apart from one subject
with mild background retinopathy, all type 1 diabetes patients were
free from tissue complications of diabetes. Twelve healthy subjects
[4 males and 8 females, age 27 ± 6 years, BMI 24 ± 2 kg/m2, hemo-
globin A1c (HbA1c) 5.2 ± 0.3%] and thirteen subjects with type 1
diabetes (8 male and 5 female, age 30 ± 11 years, BMI 24 ± 3 kg/m2,
and HbA1c 7.3 ± 1.1%, diabetes duration 9.9 ± 10.2 years) were studied
in a single blind randomized fashion (Table 1). Background insulin
treatment in the individuals with type 1 diabetes consisted of basal-
bolus (glargine/aspart or glargine/lispro) or insulin pump (aspart or
lispro) therapy. With the exception of one subject who completed
only the lispro premix portion of the study, all participants with type
1 diabetes completed both treatment arms. Studies were approved
by the Vanderbilt University Human Subjects Institutional Review
Board, and all subjects gave written and verbal informed consent.
Materials and methods
Individuals with type 1 diabetes were randomly assigned in a
1:1 ratio to one of two treatment sequences (A or B), with a
minimum 8-week washout period between treatment visits. In se-
quence A, subjects received a basal-bolus insulin regimen of insulin
glargine and insulin glulisine (glargine/glulisine) during the ﬁrst
treatment period and received premixed neutral protamine lispro
and insulin lispro 75/25 (lispro premix) during the second treat-
ment period. Those randomized to sequence B received lispro premix
and then glargine/glulisine. Healthy subjects did not receive exog-
enous insulin and participated in only one study visit.
All participants were admitted to the Vanderbilt General Clin-
ical Research Center the evening prior to the study period. Upon
admission of patients with type 1 diabetes, a retrograde intrave-
nous cannula (I.V.) was inserted under local anesthesia into the back
of a hand for blood sample collection, and a second I.V. was in-
serted in an antegrade fashion in the forearm for infusions. Upon
I.V. insertion, patients with type 1 diabetes suspended their usual
insulin regimen (long-acting insulin was taken no later than the
morning prior to admission), and intravenous regular human insulin
was infused to maintain euglycemia (target blood glucose ~5–
6.7 mmol/L). Non-diabetic controls received placement of a
retrograde I.V., as above, in the morning preceding the study. Each
subject received a standardized dinner meal and then fasted over-
night for ≥8 hours.
Meal challenge
On the study day, all subjects received three meal challenges
(08:00, 13:00 and 18:00), standardized for total caloric content and
tailored to provide a daily total of 30 kcal/kg actual body weight,
which is considered standard calorie content based on estimated
energy expenditure of moderately active healthy individuals [6].
Meals were consumed within 20 minutes. The total calories per day
were divided among meals: 1/6th at breakfast (17%), 2/6th at lunch
(33%) and 3/6th at dinner (50%) by convention. Meal calories were
approximately 50% carbohydrate, 30% lipid and 20% protein, in ac-
cordance with healthy macronutrient meal composition standards
[6].
Insulin regimens
In the diabetes groups, overnight intravenous insulin infusionwas
continued until 07:45 on themorning of the study day. In the glargine/
glulisine group, glargine was dosed at 0.35 units/kg administered
subcutaneously at 07:00 (1 hour prior to breakfast). Glulisine was
dosed at 1 unit/10 g carbohydrate per meal, administered subcuta-
neously 5 minutes prior to each meal (07:55, 12:55 and 17:55). In
the lispro premix group, total lispro premix dose was determined by
referencing the total daily dose as calculated for the glargine/
glulisine treatment period, with two-thirds administered at 07:55 (5
minutes prior to breakfast) and one-third administered at 17:55 (5
minutes prior to dinner). Thus, an equivalent insulin dosage was ad-
ministered to each type 1 diabetes patient during both protocols.
Sample collection
The handwith the retrograde I.V. was placed in a heated box (55–
60 °C) during the study so that arterialized blood could be obtained
for measurement of glucose and insulin [7]. Samples were collect-
ed hourly from 06:00 to 24:00 and every 15 minutes for 2 hours
directly following each meal.
Bioanalytical methods
Blood glucose concentrations were measured using a point-of-
care glucometer (Ascensia Elite XL, Bayer, Leverkusen, Germany) and
were subsequently conﬁrmed by measuring plasma glucose levels
using the glucose oxidasemethodwith a glucose analyzer (Beckman,
Fullerton, CA). Total serum insulin concentrations were measured
using radioimmunoassay, based on guinea pig polyvalent anti-rat
insulin antibody and radioactive iodine-labeled human insulin, vali-
dated for appropriate cross-reactivity to human insulin and each
Table 1
Baseline demographics and clinical characteristics
Characteristic Healthy (N = 12) Type 1 diabetes
(N = 13)
Age (years)a 26.7 (6.0) 30.3 (10.6)
Sex (n)
Male 4 8
Female 8 5
Height (cm) 167 (10.8) 176 (10.3)
Weight (kg) 67.9 (13.0) 74.5 (12.0)
BMI (kg/m2) 24.3 (2.4) 24.1 (2.9)
HbA1c (%) 5.2 (0.3) 7.3 (1.1)
a Values are expressed as mean (standard deviation); HbA1c = glycated hemo-
globin a1c; BMI = body mass index.
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insulin analog studied. All insulin concentration values reportedwere
derived from the human insulin standard curves, irrespective of
whether the sample contained human insulin, insulin lispro, insulin
glargine, insulin glulisine or some mixture of the aforementioned
insulins. The calibration rangewas 2.15–276 μU/mL for insulin assays.
The lower and upper limits of quantiﬁcation were 4.3 and 138 μU/
mL, respectively (Farmovs-Parexel, Bloemfontein, South Africa).
Statistical analysis
PK and PD variables were derived from systemic insulin and
glucose concentration-time data, respectively, using standard non-
compartmental techniques (i.e., trapezoidal summation for positive-
peak area-under-the-curve [AUC]). Meal-speciﬁc analysis was
conducted usingmean pre-meal baseline-normalized serum insulin
and serum glucose data from mealtime intervals. Each meal inter-
val was deﬁned as all samples obtained between the pre-meal
baselines through5hourspostprandial. Therefore, thebreakfast, lunch
and dinner intervals consisted of samples drawn from8:00 to 13:00,
13:00 to 18:00, and18:00 to 23:00, respectively. Comparison of base-
line parameters betweenpatientswith diabetes andhealthy subjects
was based on unpaired, two-tailed t test (α = 0.05), with 95% con-
ﬁdence intervals (CIs). Estimates of mean response by treatment
regimen and treatment comparisons were based on one-way anal-
ysis of variance followed by Tukey’smultiple comparison post-test.
Results
Insulin pharmacokinetics
The mean total systemic insulin dose for glargine/glulisine was
56 ± 9 units (47.6% glargine, 52.4% glulisine) and was equivalent to
lispro premix (54 ± 9 units, 75% lispro protamine, 25% lispro).
The total AUC[i] over the duration of the study was not statisti-
cally signiﬁcant between any groups (Table 2). The incremental
systemic insulin area under-the-curve (AUC[i]) during all three meal
intervals was similar between glargine/glulisine and healthy con-
trols (Table 2 and Fig. 1). Incremental AUC[i] for the breakfast interval
was greater with lispro premix treatment compared to both healthy
controls and glargine/glulisine treatment (p < 0.05). Lunchtime in-
cremental AUC[i] with lispro premix treatment was reduced
compared to healthy controls and glargine/glulisine treatment
(p < 0.001). Incremental AUC[i] during the dinner interval in the lispro
premix group was similar to healthy controls but reduced com-
pared to the glargine/glulisine group (p < 0.001).
The mean time to maximal insulin concentration (Tmax[i]) was
similar between the healthy control group and the glargine/
glulisine group for all three meals. Tmax[i] was longer in the lispro
premix group compared to the other two groups at breakfast, lunch
and dinner (p < 0.05–0.001).
The maximal change in insulin concentration from the start of
eachmeal (ΔCmax[i]) was similar in the healthy controls and glargine/
glulisine. Lispro premix ΔCmax[i] was similar to healthy controls
and the glargine/glulisine group at breakfast. Lunch time lispro
premix ΔCmax[i] (1.4 ± 1.9 μU/ml) was reduced at lunch compared
to healthy (63.4 ± 11.7 μU/ml; p < 0.001) and glargine/glulisine
(52.2 ± 6.1 μU/ml; p < 0.001). Insulin ΔCmax[i] at dinner was also
reduced in the premix group (29.6 ± 3.7 μU/ml) versus healthy
(versus 76.1 ± 17.5 μU/ml; p < 0.05) and glargine/glulisine
(78.4 ± 7.0 μU/ml; p < 0.01).
Rates of rise of meal time insulin from 0 to 30 minutes (0–30)
appear similar between healthy controls and glargine/glulisine at
eachmeal. Rateof insulin risewas signiﬁcantly slower in lispropremix
compared to healthy controls during breakfast and lunch (p < 0.05
and p < 0.001, respectively) and was signiﬁcantly slower in lispro
premix compared to glargine/glulisine at lunch anddinner (p < 0.01).
Glucose pharmacodynamics
At breakfast, incremental glucose area under-the-curve (AUC[g])
was less in healthy controls versus glargine/glulisine (p < 0.01;
Table 2, Fig. 2 and Supplemental Fig. S1). Incremental AUC[g] for the
lunch interval was similar between healthy controls and glargine/
glulisine groups but was signiﬁcantly greater with lispro premix
treatment as compared to healthy controls (p < 0.001) and glargine/
glulisine (p < 0.01). Positive incremental AUC[g] for the dinner interval
was similar among all groups.
The mean time to maximal glucose concentration (Tmax[g]) at
the breakfast interval was similar in all three groups. At lunch, Tmax[g]
was similar between glargine/glulisine and the other two groups
but delayed in the lispro premix group compared to healthy con-
trols (p < 0.01). There were no differences in Tmax[g] among the
groups at the dinner time interval.
At breakfast, the maximal change in glucose concentration
(ΔCmax[g]) was signiﬁcantly greater in both insulin treatment groups
compared to the healthy group (p < 0.05 and p < 0.001 glargine/
glulisine and lispro premix, respectively). At lunch, the blood glucose
excursion was signiﬁcantly greater in lispro premix than in healthy
controls or glargine/glulisine (p < 0.01). No differences were ob-
served during the dinner meal.
Table 2
Incremental AUC values for insulin and glucose in healthy controls and in patients with type 1 diabetes
Insulin mean AUC (μU/ml*min) (SD) p-Values
Healthy Glargine/
Glulisine
Lispro Premix Healthy vs
Glargine/Glulisine
Healthy vs
Lispro Premix
Glargine/Glulisine
vs Lispro Premix
Breakfast 4,189.8 (3,492.7) 4,366.6 (1,656.2) 7,656.1 (3,299.2) ns <0.05 <0.05
Lunch 6,939 (4,613.7) 8,437.6 (2,386.6) 1,708.4 (1,104.7) ns <0.001 <0.001
Dinner 8,301.7 (6,349.7) 11,915.0 (2,344.7) 4,822.6 (1,809.1) ns ns <0.001
Total 19,808 (4,247) 27,381 (2,309) 20,313 (2,054) ns ns ns
Glucose mean AUCg (mmol/L*min) (SD) p-Values
Healthy Glargine/
Glulisine
Lispro Premix Healthy vs
Glargine/Glulisine
Healthy vs
Lispro Premix
Glargine/Glulisine
vs Lispro Premix
Breakfast 225.6 (186.8) 746.5 (439.4) 532.6 (343.4) <0.01 ns ns
Lunch 314.3 (150.0) 577.9 (422.7) 1,394.8 (745.2) ns <0.001 <0.01
Dinner 364.3 (252.6) 346.7 (338.9) 436.3 (375.4) ns ns ns
The values for insulin mean AUC and glucose mean AUC are listed in bold font, and the standard deviations are in parentheses. AUC = area under the curve; SD = standard
deviation.
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Figure 1. Mean insulin levels over time during the study period. *Insulin AUC was signiﬁcantly different between healthy controls and lispro premix at breakfast (p < 0.05)
and lunch (p < 0.001) and signiﬁcantly different between glargine/glulisine and lispro premix at breakfast (p < 0.05), lunch and dinner (p < 0.001). Arrows below the x-axis
indicate the times at which the standardized meals were consumed. Open circles = healthy controls; black triangles = glargine/glulisine group; black squares = lispro premix
group.
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 
M
ea
n 
Bl
oo
d 
G
lu
co
se
 (m
m
ol
/L
) 
Collection Time (hours) 
Healthy 
Glargine/Glulisine 
Lispro Premix  
↑ ↑ ↑ 
* * 
Figure 2. Mean blood glucose levels over time during the study period. *Glucose AUC was signiﬁcantly different between healthy controls and glargine/glulisine at break-
fast (p < 0.01). At lunch, glucose AUC was signiﬁcantly different between healthy controls and lispro premix (p < 0.001) and between glargine/glulisine and lispro premix
(p < 0.01). Arrows below the x-axis indicate the times at which the standardized meals were consumed. Open circles = healthy controls; black triangles = glargine/glulisine
group; black squares = lispro premix group.
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Safety/hypoglycemia
No healthy patients experienced a hypoglycemic event (serum
glucose concentration <3.3 mmol/L). Ten individuals with type 1 di-
abetes experienced a total of 18 hypoglycemic events. During
treatment with glargine/glulisine, 4 patients experienced 8 hypo-
glycemic events, 2 of whom experienced 3 events each. Two, ﬁve
and one of the hypoglycemic events occurred after the breakfast,
lunch and dinner meals, respectively. During treatment with lispro
premix, 9 patients experienced 10 hypoglycemic events; all of these
events occurred prior to the lunch interval. The number of hypo-
glycemic events that occurred in the lispro premix group at lunch
was statistically greater than the number of events that occurred
in the glargine/glulisine group during the same meal interval
(p < 0.0001). There were no episodes of severe hypoglycemia in any
group.
Discussion
The current study examined the effects of three standardized
meals (breakfast, lunch and dinner) on glucose and systemic insulin
levels over a 24 hour period in individuals with type 1 diabetes ad-
ministered glargine/glulisine basal-bolus therapy or 75/25 lispro
premixed insulin twice daily and age and weight matched healthy
controls. This study demonstrates that, acutely, glargine/glulisine
more closely mimics physiologic insulin responses to meals and that
pre-lunch hypoglycemic episodes were less frequent compared to
premixed insulin.
Reviewing the available literature, we identiﬁed four other pub-
lished studies which described the use of three sequential meals
over the course of a day while measuring insulin and glucose levels
[1,8–10]. In one, responses to standardized test meals were studied
in healthy and obese participants [1]. The other three compared re-
sponses in type 1 diabetes subjects following a treatment period
with NPH insulin and mealtime insulin lispro, insulin aspart or
regular human insulin [8–10]. One of the type 1 diabetes studies
also included a non-diabetic comparator group [10]. The novelty of
this study lies in the comparison of a widely used combination of
a contemporary basal insulin (insulin glargine) and the rapid acting
analog insulin glulisine versus a premixed insulin formulation.
A number of similarities were observed between the glargine/
glulisine and healthy control groups. The incremental AUC[i] responses
were similar to healthy individuals during all three meal intervals.
Moreover, in the glargine/glulisine and healthy controls the peak
systemic insulin level (ΔCmax[i]) increased similarly between both
groups at each meal. This indicates that the increased endog-
enous insulin response to the larger carbohydrate load in healthy
subjects could be adequately-matched by the larger glulisine dose
received by subjects with type 1 diabetes with each successively
larger meal. Systemic insulin levels were measured and do not dis-
tinguish between insulin components and may not be reﬂective of
the portal concentration of insulin in the healthy controls. In healthy
individuals, insulin is secreted into the portal vein and is predomi-
nantly cleared by the liver and less so by the kidney. This creates a
portal-peripheral gradient whereby portal vein insulin levels in
healthy individuals are 3–4 fold higher than in the systemic circu-
lation. However, in individuals with type 1 diabetes, the portal vein
insulin concentration will be dependent on the release of insulin
from the subcutaneous depot. Thus, in type 1 diabetes mellitus the
portal-peripheral insulin gradient can be reversed from the phys-
iologic norm with higher peripheral as compared to hepatic vein
insulin levels. This of course will depend upon the rate and pattern
of insulin release from the subcutaneous depot.
When glulisine was administered subcutaneously only 5minutes
before each meal, the rate of rise of insulin during the ﬁrst 30
minutes of each meal appears similar to healthy controls. The rate
of rise of insulin data is most germane to the glargine/glulisine group
as glargine would not be expected to contribute in a signiﬁcant
manner to the rate of rise. The rate of rise data in the premix groups
will be reﬂective of both the intermediate and rapid acting com-
ponents. Studies have examined the effects of administering insulin
glulisine either 0–15 minutes prior to a meal or 15 minutes fol-
lowing a meal [11,12]. Pre-meal dosing of glulisine appears to be
most advantageous, with regard to reductions in post-meal glucose
excursion and 12-week HbA1c levels. Dosing guidelines currently
advise that insulin glulisine should be administered 15minutes prior
to or within 20 minutes of beginning a meal [13]. Surveys indi-
cate that patients tend to inject insulin within 15 minutes prior to
a meal and prefer shorter intervals between injection and meal-
time as a matter of ease and convenience and as an effort to avoid
hypoglycemia and improve glycemic control [14,15]. Nearly half of
type 1 diabetes patients studied in a recent report did not employ
a delay between injection and mealtime [16]. The ﬁndings from the
current study suggest that injecting glulisine only 5 minutes prior
to a meal is suﬃcient to produce increases in prandial insulin levels
in people with type 1 diabetes that are indistinguishable from age
and weight-matched healthy controls.
Previous work has provided conﬂicting results regarding whether
lispro, aspart, and glulisine have comparable PK and PD [17]. In some
PK/PD studies, absorption of insulin glulisine appeared to be faster
than absorption of lispro or aspart. Morrow et al. [18] found that
time to 50% of maximal concentration within the ﬁrst hour was 21
minutes for glulisine versus 31 and 32minutes for lispro and aspart,
respectively. Arnolds et al. [19] found that the time to 10 and 20%
of maximum insulin concentration was shorter for glulisine versus
aspart, and correspondingly, the AUC for glucose infusion rate (to
maintain euglycemia) was 30 mg/kg in the glulisine group versus
16 mg/kg in the aspart group. Similarly, Heise et al. [20] found that
the time to 10% of total AUC insulin was shorter with a 0.2 U/kg dose
glulisine compared to an equivalent dose of lispro. Additionally, the
AUC for the glucose infusion rate in the ﬁrst hour (102.3mg/kg versus
83.1 mg/kg) was greater following glulisine as compared to lispro.
The apparent increased rate of absorption of glulisine may be at-
tributable to the fact that glulisine is prepared as a zinc-free injection,
whereas the presence of zinc in the aspart and lispro injections may
promote hexamer formation at the injection site [21].
Lispro premix insulin was dosed as two-thirds of the total daily
dose injected prior to breakfast in an effort to cover both the break-
fast and lunch meals and the ﬁnal one-third prior to dinner. Thus,
while glucose exposure, as measured by incremental AUC[g], was
similar in the glargine/glulisine and lispro premix groups during the
breakfast period, the lispro premix insulin dose resulted in a sig-
niﬁcantly larger incremental AUC[i] compared to both the healthy
group and the glargine/glulisine group. Additionally, in the lispro
premix group, blood glucose levels fell below baseline prior to lunch,
and all ten of the hypoglycemic events in the lispro premix group
occurred in the late breakfast period. Despite the exaggerated break-
fast time AUC[i] in the lispro premix group, insulin concentrations
in this group were not suﬃcient at lunch. The AUC[i] following lispro
premix was approximately one-quarter of the AUC[i] observed in
healthy controls and nearly one-ﬁfth of the AUC[i] in the glargine/
glulisine group. Correspondingly, the lunch interval AUC[g] was
substantially greater than observed in the healthy and glargine/
glulisine groups. Blood glucose also did not return to pre-breakfast
levels in the lispro premix after lunch or dinner. Therefore, the lispro
premix increased the risk of hypoglycemia between breakfast and
lunch and failed to provide lunch time meal coverage, exposing pa-
tients to a large, long-duration postprandial glucose excursion.
For patients with type 1 diabetes, premix insulin is not in-
cluded as an option within recommendations cited by guidelines
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provided by the American Diabetes Association or the American As-
sociation of Clinical Endocrinologists [22–24], as intensive insulin
therapies (basal-bolus therapy with three or more injections or con-
tinuous subcutaneous insulin infusion therapy) provide superior
glycemic control [25]. Despite the lack of recommendations, pro-
viders may still elect to prescribe this treatment plan, as it negates
the need to count carbohydrates at meals and could be advanta-
geous in situations of low literacy or poor adherence [26].
Furthermore, use of premix insulin for type 1 diabetes is more prev-
alent in nations outside of the USA [27–29]. In an analysis of 75 non-
Western countries identiﬁed as members of the International
Diabetes Federation, 25 countries provided guidelines for use of phar-
macotherapy for type 1 diabetes, of which 60% included basal-
bolus and premix regimens as ﬁrst-line therapeutic options [30].
A smaller proportion of subjects in the glargine/glulisine treat-
ment group (4/12) experienced hypoglycemic events than in the
lispro premix treatment group (9/13). Notably, this difference oc-
curred despite the fact that lunch and dinner time insulin exposure
was statistically greater in the glargine/glulisine group compared
to the lispro premix group. Because this was a one-day study and
the mealtime glulisine:carbohydrate dose was ﬁxed, some sub-
jects may have received a larger insulin:carbohydrate ratio than
needed. This may have been the case in two subjects in the glargine/
glulisine group who each experienced three hypoglycemic events.
Clinically, the basal-bolus regimen allows for ﬂexibility in real time,
and the glulisine:carbohydrate ratio could be adjusted for pa-
tients’ needs at each meal to avoid postprandial hypoglycemia.
A healthy control group was included as a means of assessing
the degree to which the two insulin therapies studiedmatched phys-
iologic responses to meals. Overall, insulin sensitivity was expected
to be similar between the individuals with type 1 diabetes and the
healthy controls. The individuals with type 1 diabetes had a normal
BMI and good metabolic control with a mean HbA1c value of 7.3%.
For control purposes, insulin dosing was standardized by admin-
istering a set ratio of insulin to carbohydrates. Glulisine was dosed
in a conventional manner of 1 unit for every 10 gm carbohydrate,
which approximated the 450-rule (450/total daily insulin) for dosing
recommendations for the meal-time insulin to carbohydrate ratio
[31]. This represented an applicable starting ratio typically used in
clinical practice. The conventional strategy for dosing with lispro
premix insulin is to split the injection into two doses, two-thirds
in the morning and one-third in the evening [26,32,33], as was done
in this study.
Limitations of this study include the fact that it was a small study
that entailed only one day of monitoring for each insulin regimen.
As a set ratio of insulin to carbohydrate was used, the effects of a
different carbohydrate load or insulin to carbohydrate ratio or the
addition of a pre-meal correction scale cannot be predicted based
on the current data. Additionally, individualization of insulin dosing
parameters (i.e., insulin to carbohydrate ratios or addition of a cor-
rection factor) may have further demonstrated the ability of basal
bolus therapy tomimic normal healthy physiology to a greater extent.
Premix insulin dosing was ﬁxed for the purposes of this study;
however, dosing of premix could be adjusted based on the meal
content. Other experimental designs such as comparing the PK/
PD effects of the two insulin regimens before a single standardized
meal (e.g. breakfast) may have been more favorable toward the use
of 75:25 premix analog insulin. One could consider that using a 50/
50 analog premix formulation would be another comparator to this
study’s distribution of glulisine to glargine which was approxi-
mately 50/50. However, the presence of additional fast-acting pre-
prandial insulin before breakfast in the premix insulin might also
contribute to a greater prevalence of late morning/pre-lunch hy-
poglycemia. Our study of individuals with type 1 diabetes mellitus
provides a very useful model to investigate the PK characteristics
of a subcutaneous injected insulin without the confounding effects
of changing endogenous insulin leads; however, the study design
did not include enough data points to additionally quantify the rate
of rise of insulin (i.e. the times to 10%, 20% or 50% max absorption).
Strengths of the study include the three mixed-meal, day-long
design with a controlled observation period that included fre-
quent blood sampling, which provided information about insulin
pharmacokinetics and pharmacodynamics throughout the day. The
crossover study design prevented discrepancies in insulin sensi-
tivity between the two treatment groups and allowed for equal total
insulin doses for each individual during both treatment arms. Total
dose and total AUC[i] were similar, demonstrating internal consis-
tency of the study design. The participants with type 1 diabetes were
metabolically well controlled (HbA1c 7.3%) and blood glucose was
tightly controlled during the night before the study, indicating that
glucotoxicity was not a confounding factor in observations.
Conclusion
In summary, this study was designed to approximate the typical
daily meal intake of a patient with type 1 diabetes who consumes
breakfast, lunch and dinner. The PK of the glargine/glulisine treat-
ment mimicked patterns of endogenous insulin levels in healthy
controls, as evidenced by similarities in incremental AUC[i], Tmax[i],
and ΔCmax[i] in the two groups. Additionally, upon glulisine injec-
tion only 5 minutes before a meal, systemic insulin levels showed
a similar rate of rise as endogenous insulin in healthy individuals.
While premixed analog insulin allows for a simpliﬁed dosing
regimen, it is at the expense of an increased risk for hypoglycemia
and lunch time postprandial hyperglycemia. This study was
hypothesis-generating and allows opportunities to further study dif-
fering approaches of insulin delivery, meal content and dosing of
insulin regimens tailored to an individual patient and his/her daily
meal intake. This supports the importance of conducting studies that
cover an entire day, and provide additional information beyond that
observed with a simple one-meal challenge. We conclude that a
regimen of basal insulin (glargine) and glulisine (injected 5 minutes
before three standard meals) for people with type 1 diabetes can
reproduce physiologic insulin responses observed in age and BMI
matched healthy controls.
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